Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Serum proteomics in multiple sclerosis disease progression.
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.
Natalizumab (TYSABRI) and multiple sclerosis. With longer follow-up: even more toxic than suspected.
Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4.
Pathological differences between white and grey matter multiple sclerosis lesions.
Increased sleep fragmentation in experimental autoimmune encephalomyelitis.
Anti-aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Baló's Concentric Lesions.
Correction: Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response.
Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review.
Fatigue in multiple sclerosis is not due to sleep apnoea.
Disconnection mechanism and regional cortical atrophy contribute to impaired processing of facial expressions and theory of mind in multiple sclerosis: a structural MRI study.
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.
Induction of regulatory T cells in Th1-/Th17-driven experimental autoimmune encephalomyelitis by zinc administration.
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.
[The possibility of using music therapy in neurology on the example of multiple sclerosis].
17β-estradiol enhances the efficacy of adipose-derived mesenchymal stem cells on remyelination in mouse model of multiple sclerosis.
Multiple sclerosis: Defect in peripheral B-cell tolerance identified in MS.
Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
Guillain-Barre syndrome following dengue fever and literature review.
Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe.
Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
Low dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease.
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method.
Pages
« first
‹ previous
…
548
549
550
551
552
553
554
555
556
…
next ›
last »